PET and Clinical Evidence for Neuroprotective Effects of KM-819 on MSA
Objective: To assess the effect of KM-819 on the progression of multiple system atrophy (MSA). Background: Parkinson’s brain is associated with increased expression of the…Cerebral Glucose Metabolic Features of GBA-Parkinson’s Disease as a window into cognitive impairment
Objective: to investigate cerebral glucose metabolism via fluorodeoxyglucose positron emission tomography (FDG-PET) and its correlation to clinical features in Parkinson’s disease (PD) patients with GBA1…Topographical heterogeneity of cholinergic system status in Multiple System Atrophy: A series report
Objective: To characterize individual-level topographical patterns of cholinergic upregulation and downregulation in Multiple System Atrophy (MSA) using a whole brain voxel-wise approach. Background: MSA is…Uncovering the heterogeneity of spatiotemporal trajectories of neurodegeneration in Parkinson’s disease: an early-phase 18F-FP-CIT PET study
Objective: To define the subtypes of Parkinson’s disease (PD) based on the spatiotemporal progression patterns of cerebral hypoperfusion. Background: Early-phase 18F-FP-CIT PET images, which are…Metabolic Patterns in Multiple System Atrophy: Brain Network Insights from Spatial ICA of FDG-PET
Objective: This study employs spatial independent component analysis (ICA) on 18F-fluorodeoxyglucose (FDG)-PET imaging to decompose metabolic heterogeneity in Multiple system atrophy (MSA), identifying key brain…Understanding the relationship between synaptic density and dopamine transporter availability in Parkinson’s disease
Objective: To evaluate how disease duration in PD affects the coupling of DAT (18F-FE-PE2I) and SV2A density (11C-UCB-J) in the nigrostriatal regions (where both tracers…Spatial Metabolic Covariance Networks in PSP: Implications for Symptomatology and their Neural Basis
Objective: This study aimed to apply spatial ICA to 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) data from PSP patients and healthy controls (HCs) to identify…Asymptomatic GBA1 Mutation Carriers Have Increased Cortical Cholinergic Activity
Objective: The objective of this study was to assess cholinergic activity changes in patients with Parkinson’s disease carrying GBA1 variants(GBA-PD) and in non-manifesting carriers(GBA-NMC) using…Brain Target Engagement and Pharmacokinetic-Enzyme Occupancy (PK-EO) Relationship of FNP-223: A Novel Oral OGA Inhibitor for Progressive Supranuclear Palsy – Phase 1 PET Study
Objective: To determine the brain O-GlcNAcase (OGA) occupancy, following a single oral dose of FNP-223 (formerly ASN90) and to determine PK-EO relationship. Background: Preclinical evidence…STN-DBS Improves Motor and Cognitive Functions Associated with Increased Occipital Metabolism in PDD Patients
Objective: The study aims to determine whether STN-DBS brings about clinical benefits for Parkinson’s disease dementia (PDD) patients and its association with metabolic change in…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 40
- Next Page »